AAN: Hormone Exposure Affects Parkinson's Risk
Age at menopause, parity and hormone therapy use may have variable effects on disease risk
WEDNESDAY, Feb. 25 (HealthDay News) -- In postmenopausal women, reproductive factors and hormone therapy use may affect the risk of Parkinson's disease, according to research that will be presented April 25-May 2 at the annual meeting of the American Academy of Neurology in Seattle.
Rachel Saunders-Pullman, M.D., of the Beth Israel Medical Center in New York City, and colleagues assessed data on 83,482 participants in the Observational Study of the Women's Health Initiative, including 73,973 women who experienced natural menopause and 7,763 who experienced surgical menopause.
The researchers found that the risk of Parkinson's disease was significantly lower among women experiencing natural menopause who had a fertile lifespan greater than 39 years compared to those with a fertile lifespan less than 33 years (hazard ratio, 0.76). They found that the risk was higher among women with at least four pregnancies than in those with three or fewer pregnancies (hazard ratio, 1.20). Among women with surgical menopause, they found that those who used hormone therapy had a nearly doubled risk compared to non-users (hazard ratio, 1.92).
"Prior postmenopausal hormone therapy use was not associated with Parkinson's disease among women with natural menopause," the authors write.